Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Children with severe atopic dermatitis (AD), refractory to conventional systemic treatment as well as single-agent biologic and Janus kinase inhibitor (JAKi) such as abrocitinib, currently face a lack of treatment options. In response to this clinical conundrum, we present three cases of severe and refractory pediatric AD successfully managed with combined dupilumab and abrocitinib. These children had exhausted all conventional treatments and had undergone treatment with both dupilumab and abrocitinib individually, as well as dupilumab in conjunction with methotrexate. It was only when the combination of dupilumab and abrocitinib was introduced that they finally achieved noticeable and sustained improvements in disease control.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950800 | PMC |
| http://dx.doi.org/10.1111/pde.15761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.
Dermatol Ther (Heidelb)
September 2025
Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada.
Introduction: Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and effective in improving itch and lesion clearance in patients ≥ 12 years old.
View Article and Find Full Text PDFResponse to Wang et al., "Comments on 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
J Am Acad Dermatol
August 2025
Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China; Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Engineering Technology Research and Development Center for Ex
Comments on "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
J Am Acad Dermatol
August 2025
College of Pharmaceutical Sciences, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding, Hebei, 071000, China; State Key Laboratory of New Pharmaceutical Preparations and Excipients, Baoding, Hebei, 071000, China.
Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.
Curr Issues Mol Biol
August 2025
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation and epidermal barrier dysfunction. Advances in understanding the interplay of genetic predisposition, cytokine signaling, and environmental triggers have led to the emergence of targeted therapies. Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options.
View Article and Find Full Text PDFResponse to Goleva et al, "Response to Chang et al's 'Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis'".
J Am Acad Dermatol
August 2025
Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China; Guangdong Provincial Engineering Technology Research and Development Center for Ex